LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Average Target Price from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $94.57.

Several research firms have commented on LMAT. Oppenheimer reissued an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Barrington Research upped their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.79% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of LMAT. Driehaus Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the period. F M Investments LLC purchased a new stake in LeMaitre Vascular in the 2nd quarter worth approximately $7,443,000. DF Dent & Co. Inc. boosted its stake in shares of LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after buying an additional 53,797 shares during the period. Nicholas Investment Partners LP purchased a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $3,900,000. Finally, Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after acquiring an additional 36,850 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 1.4 %

Shares of NASDAQ LMAT opened at $92.63 on Monday. LeMaitre Vascular has a 12-month low of $52.88 and a 12-month high of $109.58. The company has a market cap of $2.08 billion, a PE ratio of 50.62, a P/E/G ratio of 2.47 and a beta of 0.93. The stock has a 50 day simple moving average of $97.76 and a 200-day simple moving average of $90.27.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter in the prior year, the business posted $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. Sell-side analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were given a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.